Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors

Area of Science:

• Oncology
• Immunotherapy
• Cancer Biology

Background:

• Immune-checkpoint inhibitors (ICIs) represent a significant advancement in cancer therapy.
• Hyperprogressive disease (HPD) is an emerging, rare complication characterized by rapid disease acceleration following ICI treatment.
• Understanding HPD is crucial as immunotherapy use expands.

Purpose of the Study:

• To report an unusual case of HPD.
• To highlight HPD occurring with two distinct ICIs in the same patient.
• To discuss implications for future immunotherapy strategies.

Main Methods:

• Case report of a 77-year-old male with stage IV lung squamous cell carcinoma.
• Patient received pembrolizumab after viral transduction and radiation therapy, experiencing HPD.
• Patient later received atezolizumab, again progressing rapidly (HPD).

Main Results:

• The patient experienced exponential disease progression after the first cycle of pembrolizumab.
• Following a switch to chemotherapy and then atezolizumab, the patient again showed substantial disease progression after a single infusion.
• This represents the first reported instance of HPD with two different ICIs in the same individual.

Conclusions:

• HPD is a rare but severe complication of immunotherapy with significant mortality.
• This case suggests that prior HPD with one ICI may contraindicate the use of another ICI.
• Further research is needed to identify patients at risk for HPD and to understand its mechanisms.